Amyloidosis classification: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 15: | Line 15: | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Syndrome | ! align="center" style="background:#4479BA; color: #FFFFFF;" + |Clinical Syndrome | ||
|- | |- | ||
| style="background:#DCDCDC;" | | style="background:#DCDCDC;" |'''AL (primary amyloidosis)''' | ||
|[[Light chain|Light chains]] of [[Immunoglobulin|immunoglobulines]] (most common type) | |[[Light chain|Light chains]] of [[Immunoglobulin|immunoglobulines]] (most common type) | ||
|[[Monoclonal gammopathy]] | |[[Monoclonal gammopathy]] | ||
|- | |- | ||
| style="background:#DCDCDC;" | | style="background:#DCDCDC;" |'''AA (secondary amyloidosis)''' | ||
|[[Serum amyloid A|Serum amyloid A protein]] | |[[Serum amyloid A|Serum amyloid A protein]] | ||
|[[Chronic inflammation|Chronic inflammatory diseases]] | |[[Chronic inflammation|Chronic inflammatory diseases]] | ||
| Line 29: | Line 29: | ||
| style="background:#DCDCDC;" |'''ATTRwt''' | | style="background:#DCDCDC;" |'''ATTRwt''' | ||
|Wild-type [[transthyretin]] | |Wild-type [[transthyretin]] | ||
|[[Senile]] [[restrictive cardiomyopathy]] | |[[Senile]] [[restrictive cardiomyopathy]]/[[Transthyretin]]-related amyloidosis wild-type | ||
|- | |- | ||
| style="background:#DCDCDC;" |'''AH''' | | style="background:#DCDCDC;" |'''AH''' | ||
| Line 43: | Line 43: | ||
|- | |- | ||
! rowspan="3" style="background:#DCDCDC;" |Systemic amyloidosis | ! rowspan="3" style="background:#DCDCDC;" |Systemic amyloidosis | ||
! style="background:#DCDCDC;" | ! style="background:#DCDCDC;" |Primary amyloidosis (AL) | ||
| | | | ||
*Aggregation and deposition of [[immunoglobulin]] [[Light chain|light chains]] that usually produced by [[plasma cell]] clones | *Aggregation and deposition of [[immunoglobulin]] [[Light chain|light chains]] that usually produced by [[plasma cell]] clones | ||
| Line 54: | Line 54: | ||
*[[Purpura]] and an unexplained [[Hemorrhagic diathesis|bleeding diathesis]] | *[[Purpura]] and an unexplained [[Hemorrhagic diathesis|bleeding diathesis]] | ||
|- | |- | ||
! style="background:#DCDCDC;" | ! style="background:#DCDCDC;" |Secondary amyloidosis (AA) | ||
| | | | ||
*Chronic [[inflammation]] ([[Tuberculosis|TB]], [[familial mediterranean fever]], [[rheumatoid arthritis]] and [[multiple myeloma]]) | *Chronic [[inflammation]] ([[Tuberculosis|TB]], [[familial mediterranean fever]], [[rheumatoid arthritis]] and [[multiple myeloma]]) | ||
| Line 61: | Line 61: | ||
*[[Congestive heart failure|Heart failure]] | *[[Congestive heart failure|Heart failure]] | ||
|- | |- | ||
! style="background:#DCDCDC;" | ! style="background:#DCDCDC;" |Hereditary amyloidosis | ||
| | | | ||
*Amyloidogenic [[Mutation|mutations]] and subsequently deposition of [[Amyloid|amyloids]] | *Amyloidogenic [[Mutation|mutations]] and subsequently deposition of [[Amyloid|amyloids]] | ||
Revision as of 17:41, 29 October 2019
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis classification On the Web |
|
American Roentgen Ray Society Images of Amyloidosis classification |
|
Risk calculators and risk factors for Amyloidosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2]
Overview
Amyloidosis may be classified on the basis of type of amyloidogenic protein and associated clinical syndromes into primary (AL) amyloidosis, secondary (AA) amyloidosis, familial (AF) amyloidosis, transthyretin (ATTRwt) amyloidosis and dialysis-associated (AH) amyloidosis. It can also be classified based on extent of organ system involvement.
Classification
Classification Based on Precursor of Amyloidogenic Protein: [1][2]
| Type | Amyloidogenic Protein/Fibril | Clinical Syndrome |
|---|---|---|
| AL (primary amyloidosis) | Light chains of immunoglobulines (most common type) | Monoclonal gammopathy |
| AA (secondary amyloidosis) | Serum amyloid A protein | Chronic inflammatory diseases |
| AF | Mutant transthyretin, A1-apolipoprotein, gelsolin, fibrinogen, etc. | Familial polyneuropathy/cardiomyopathy/nephropathy |
| ATTRwt | Wild-type transthyretin | Senile restrictive cardiomyopathy/Transthyretin-related amyloidosis wild-type |
| AH | ß2-microglobulin | Long-term hemodialysis |
Classification Based on Organ Involvement:[3][4]
| Classification | Subtypes | Causes | Clinical Features |
|---|---|---|---|
| Systemic amyloidosis | Primary amyloidosis (AL) |
|
|
| Secondary amyloidosis (AA) |
|
||
| Hereditary amyloidosis | |||
| Organ-specific amyloidosis | Renal amyloidosis |
|
|
| Cardiac amyloidosis | |||
| Hepatic amyloidosis |
| ||
| Amyloid neuropathy | |||
| Gastrointestinal amyloidosis |
|
Refrences
- ↑ Khoor A, Colby TV (February 2017). "Amyloidosis of the Lung". Arch. Pathol. Lab. Med. 141 (2): 247–254. doi:10.5858/arpa.2016-0102-RA. PMID 28134587.
- ↑ Benson MD, Buxbaum JN, Eisenberg DS, Merlini G, Saraiva M, Sekijima Y, Sipe JD, Westermark P (December 2018). "Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee". Amyloid. 25 (4): 215–219. doi:10.1080/13506129.2018.1549825. PMID 30614283. Vancouver style error: initials (help)
- ↑ Wechalekar AD, Gillmore JD, Hawkins PN (June 2016). "Systemic amyloidosis". Lancet. 387 (10038): 2641–2654. doi:10.1016/S0140-6736(15)01274-X. PMID 26719234.
- ↑ Falk RH, Alexander KM, Liao R, Dorbala S (September 2016). "AL (Light-Chain) Cardiac Amyloidosis: A Review of Diagnosis and Therapy". J. Am. Coll. Cardiol. 68 (12): 1323–41. doi:10.1016/j.jacc.2016.06.053. PMID 27634125.
|
Amyloidosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Amyloidosis classification On the Web |
|
American Roentgen Ray Society Images of Amyloidosis classification |
|
Risk calculators and risk factors for Amyloidosis classification |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [3]; Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[4]
Overview
Classification
Amyloidosis may be classified based on precursor of amyloidogenic protein into different subtypes, include:[1][2]
| Type | Amyloidogenic protein/ fibril | Clinical syndrome |
|---|---|---|
| AL | Light chains of immunoglobulines (most common type) | Monoclonal gammopathy |
| AA | Serum amyloid A protein | Chronic inflammatory diseases |
| AF | Mutant transthyretin, A1-apolipoprotein, gelsolin, fibrinogen, etc. | Familial polyneuropathy/cardiomyopathy/nephropathy |
| ATTRwt | Wild-type transthyretin | Senile restrictive cardiomyopathy _ Transthyretin-related amyloidosis wild-type |
| AH | ß2-microglobulin | Long-term hemodialysis |
References
- ↑ Real de Asúa D, Costa R, Galván JM, Filigheddu MT, Trujillo D, Cadiñanos J (2014). "Systemic AA amyloidosis: epidemiology, diagnosis, and management". Clin Epidemiol. 6: 369–77. doi:10.2147/CLEP.S39981. PMC 4218891. PMID 25378951.
- ↑ Misumi Y, Ando Y (July 2014). "[Classification of amyloidosis]". Brain Nerve (in Japanese). 66 (7): 731–7. PMID 24998818.